The efficacy of immunotherapy can be undermined by the development of an immune response against a drug/antibody mediated by anti-drug antibodies (ADAs) in treated patients. We present the first label-free EGOFET immunosensor that integrates a biological drug, Nivolumab (Opdivo©), as a specific recognition moiety to quantitatively and selectively detect ADAs against the drug. The limit of detection is 100 fM. This demonstration is a prelude to the detection of ADAs in a clinical setting in the treatment of different pathologies, and it also enables rapid screening of biological drugs for immunogenicity
Tacrolimus (FK506) is an immunosuppressant drug (ISD) used to prevent organ rejection after transpla...
Herein a label-free immunosensor based on electrolyte-gated organic field-effect transistor (EGOFET)...
This article takes a special focus on signal amplification technologies in immunoassays and new gene...
Therapeutic monoclonal antibodies (TmAb) have emerged as effective treatments for a number of cancer...
Concentration–therapeutic efficacy relationships have been observed for several therapeutic monoclon...
Monitoring the levels of therapeutic antibodies in individual patients would allow patient-specific ...
Therapeutic monoclonal antibodies (mAbs) are currently the most effective medicines for a wide range...
An overview of cytokine biosensing is provided, with a focus on the opportunities provided by organi...
Recombinant DNA technology and corresponding innovations in molecular biology, chemistry and medicin...
In this contribution, we propose a label-free immunosensor, based on a novel type of electrolyte-gat...
Engineering: 3rd Place (The Ohio State University Denman Undergraduate Research Forum)Field effect t...
Immunotherapy with monoclonal antibodies targeting the programmed-death-1 (PD-1) receptor has become...
AbstractMepolizumab, a humanized IgG1 monoclonal antibody that blocks native homodimeric interleukin...
Antibodies are among the most relevant biomolecular targetsfordiagnostic and clinical applications. ...
Biorecognition is a central event in biological processes in the living systems that is also widely ...
Tacrolimus (FK506) is an immunosuppressant drug (ISD) used to prevent organ rejection after transpla...
Herein a label-free immunosensor based on electrolyte-gated organic field-effect transistor (EGOFET)...
This article takes a special focus on signal amplification technologies in immunoassays and new gene...
Therapeutic monoclonal antibodies (TmAb) have emerged as effective treatments for a number of cancer...
Concentration–therapeutic efficacy relationships have been observed for several therapeutic monoclon...
Monitoring the levels of therapeutic antibodies in individual patients would allow patient-specific ...
Therapeutic monoclonal antibodies (mAbs) are currently the most effective medicines for a wide range...
An overview of cytokine biosensing is provided, with a focus on the opportunities provided by organi...
Recombinant DNA technology and corresponding innovations in molecular biology, chemistry and medicin...
In this contribution, we propose a label-free immunosensor, based on a novel type of electrolyte-gat...
Engineering: 3rd Place (The Ohio State University Denman Undergraduate Research Forum)Field effect t...
Immunotherapy with monoclonal antibodies targeting the programmed-death-1 (PD-1) receptor has become...
AbstractMepolizumab, a humanized IgG1 monoclonal antibody that blocks native homodimeric interleukin...
Antibodies are among the most relevant biomolecular targetsfordiagnostic and clinical applications. ...
Biorecognition is a central event in biological processes in the living systems that is also widely ...
Tacrolimus (FK506) is an immunosuppressant drug (ISD) used to prevent organ rejection after transpla...
Herein a label-free immunosensor based on electrolyte-gated organic field-effect transistor (EGOFET)...
This article takes a special focus on signal amplification technologies in immunoassays and new gene...